82 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
of the political and security situation in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion of Ukraine
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
therapeutic candidates;
market conditions;
payments to the IIA; and
the impact of any resurgence of the COVID-19 pandemic and the military
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
of the COVID-19 pandemic, the Russian invasion of Ukraine, the declared war by Israel against Hamas and the military campaigns against Hamas and other
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
; statements as to the impact of the political and security situation in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion of Ukraine, the declared war by Israel against Hamas and the military
6-K
EX-99
s9iv3 4t2wsoh9s76t8
6 May 24
Current report (foreign)
7:14am
6-K
EX-99.1
ew78n3g50pj5
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
EX-99
2lmdsjkodnzw vnk
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
EX-99.1
d6k6bx9v
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
ouol2
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
abscmyfcf5v
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
boutu
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
fmhtfpg8gt
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
46anw2c9ef2lso7
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
cqoekdu75uaech2
16 Feb 24
Current report (foreign)
7:07am
6-K
EX-99
82h28bzx
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
q5n42hipn1 2k
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
pal5eu76l48 f8gsz
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
pju2hljoy2nevjs7nb
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am